David Strobl

Lower eGFR in type 1 diabetes doesn't appear to raise DKA risk. This encourages research into drugs like SGLTi, which may increase DKA risk but offer crucial kidney protection.

Read here ➡️ doi.org/10.2337/dc25-1955

Figure showing the putative molecular mechanisms of the liver–gut–muscle axis in metabolic dysfunction-associated steatotic liver disease and sarcopenia.

Featured in our March issue: Ming-Hua Zheng and colleagues review the connections between MASLD, sarcopenia and metabolic syndrome and discuss how care for patients affected by these diseases is evolving rdcu.be/e4fae
#EndoSky #MedSky

Wir durften als Young Diabetologists die 1. Winter School für Kolleg:innen veranstalten: Im Programm gab es praxisrelevante Workshops & Fortbildung zu medizinischer Gesprächsführung. 🤓🏔️📚💉Auch eine weitere Folge für Öglykäm wurde aufgezeichnet. 🎧 @yd-austria.bsky.social

Figure showing the effect of statin versus placebo on events listed in statin SmPCs, subdivided by component parts. Results for two outcomes with fewer than ten events are not shown in the figure, but are included in the appendix. FDR=false discovery rate. LFT=liver function test. RBC=red blood cell. RR=rate ratio. SmPC=Summary of Product Characteristics. *FDR significant at the 5% level; RR for results FDR-significant at the 5% level are indicated by black circles and RR for results not FDR-significant at the 5% level indicated by grey circles. †Excluded from FDR testing; RR for results excluded from FDR testing indicated by white circles.

Almost all side effects on statin labels not caused by statins, finds major meta-analysis; authors call for labels to be updated.

Find out more 👉 spkl.io/63324AsjHO

From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 #Diabetes Mellitus and #CKD

https://doi.org/10.1016/j.ekir.2025.09.027

#KIRReview

🎬Episode 7 of Best of #EASD2025 is live! Dr. Michael Leutner (Medical University of Vienna) shares his key highlights, focusing on the SOUL trial and new insights into #HeartFailure and peripheral artery disease in #T2D.
🎥Watch👉 youtu.be/EgoIFh2bT-M?...
#Diabetes #DiabetesResearch

Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) ca. 2026 from @kdigo.org
#Nephpearls #NephSky

👉 kdigo.org/guidelines/a...

The Entire New Yorker Archive Is Now Fully Digitized For the first time, every cover, article, and issue in the magazine’s hundred-year history can be enjoyed on newyorker.com.

This is big and a very long time coming! Your TBR pile just got 100 years longer. www.newyorker.com/news/press-r...

So wunderbar!

Now that is probably as reduced as possible 👏

Yes. This is a game changer. Beyond being able to replace AVS, it allows one to “see” the underlying pathological contributors to a large proportion of “idiopathic” hypertension. This is another piece of evidence that should make clinicians rethink the pathogenesis and treatment of hypertension

😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?

🖇️: rdcu.be/eLAde

#LiverSky @georg-semmler.bsky.social

Interesting company choice, but I'm glad its not gone entirely. Thanks for the insight!

So they didn't discontinue Bimagrumab?

Log In - pdfFiller

Paper of the Month#62

Es mehrt sich die Evidenz zur Effektivität von GLP1 RA bei Menschen mit T1D.
Dieses Mal berichten wir über eine Studie bei denen Semaglutide bei (vorwiegend adipösen) Menschen m. T1D unter Pumpen/AID Systemen eingesetzt wurde

Link zum PotM: 🖇️: www.pdffiller.com/s/Z2_qi9tBEB

Which makes it even worse one cannot attend online 😔

FINE-ONE (Finerenone in albuminuric T1DM) results should be out soon/will be presented at ASN kidney week :)

Core Curriculum by Biff F. Palmer and Deborah J. Clegg:

Mixed Acid-Base Disturbances: Core Curriculum 2025

bit.ly/Palmer25CC (FREE)

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...

New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#OpenAccess

#MedSky #EndoSky #RenalSky

Going to add this to my lecture slides.

I think I'm speaking for a lot of people here when I say it would be much appreciated if you post it on bluesky simultaneously.

Ein Held meiner Kindheit, nebst Mira Lobe, Astrid Lindgren, Janosch und dem immer noch innig geliebten Erwin Moser.

Excellent decision, easy to remember, imho. Although I'd much rather be in a Sean Connery than in a Roger Moore trial ;-)

Yes, absolutely, aiming to phase out insulin as soon as possible.

I tend to use basal insulin a lot (mostly after Metformin, SGLT2i and Incretin-based), for reaching a1c goals.

Delighted to share our new review in @cp-trendsendomet.bsky.social on Repurposing metabolic drugs (GLP-1s & SGLT2s) as anti-inflammatory agents! Thanks to @nickjonesimmuno.bsky.social for this joint effort
doi.org/10.1016/j.te...

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases

doi.org/10.1093/ndt/...

PotM#60

Die Heilung von Typ 1 Diabetes durch Stammzelltherapie (in ausgewählten Patient*innengruppen) scheint (zumindest für eine begrenzte Dauer) möglich.

Eine rezente Studie dazu, heute präsentiert von
@antoniakietaibl.bsky.social

Link zum PotM🖇️: pdf.ac/52DKQX

Das Museum der Kunst der Verlorenen Generation in Salzburg empfehle ich jedem Besucher.